BlackRock Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

BlackRock Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$127K	Buy	904 +143	+19%	+$19.3K	﹤0.01%	2922
2016 Q3	$111K	Buy	761 +100	+15%	+$12K	﹤0.01%	2978
2016 Q2	$67K	Buy	661 +7	+1%	+$909	﹤0.01%	3142
2016 Q1	$87K	Hold	654	–	–	﹤0.01%	2978
2015 Q4	$130K	Sell	654 -283	-30%	-$61.3K	﹤0.01%	2804
2015 Q3	$148K	Sell	937 -17,956	-95%	-$4.8M	﹤0.01%	2893
2015 Q2	$7.71M	Buy	18,893 +310	+2%	+$134K	0.01%	844
2015 Q1	$8.53M	Sell	18,583 -21,903	-54%	-$9.44M	0.01%	840
2014 Q4	$22.7M	Sell	40,486 -7,792	-16%	-$4.43M	0.02%	516
2014 Q3	$25.3M	Sell	48,278 -851	-2%	-$480K	0.03%	511
2014 Q2	$34.3M	Buy	49,129 +6,620	+16%	+$3.08M	0.03%	435
2014 Q1	$19.7M	Buy	42,509 +20,721	+95%	+$10.5M	0.02%	553
2013 Q4	$7.49M	Buy	+21,788	New	+$6.02M	0.01%	891

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Advisors's KPTI Position: Q4 2016 in Review

BlackRock Advisors increased its Karyopharm Therapeutics (KPTI) stake by 19% in Q4 2016, buying an estimated $19.3K and bringing the position to 904 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

BlackRock Advisors first reported a position in KPTI in Q4 2013 and has held it in 13 quarters since. The position peaked at $34.3M in Q2 2014. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

BlackRock Advisors held 904 shares of Karyopharm Therapeutics worth $127K as of Q4 2016.
BlackRock Advisors bought 143 Karyopharm Therapeutics shares in Q4 2016, an estimated $19.3K.
Karyopharm Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2922 holding.
BlackRock Advisors first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 13 quarters since.
BlackRock Advisors's Karyopharm Therapeutics position peaked at $34.3M in Q2 2014.
86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.